Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group

Ignace Vergote; Els Van Nieuwenhuysen; Stefanie De Waele; Christof Vulsteke; Caroline Lamot; Heidi Van den Bulck; Nele Claes; Marie-Pascale Graas; Guy Debrock; Isabelle Spoormans; Peter Vuylsteke; Brigitte Honhon; Didier Verhoeven; Daan De Maeseneer; Luc Dirix; Jeroen Mebis; Philippe Vroman; Hannelore Denys; Corina Martinez Mena; Gino Pelgrims; Mona Van Steenberghe; Toon van Gorp; Christine Gennigens

doi:10.1136/ijgc-2021-003190

Citation Tools

other Versions

You are currently viewing an earlier version of this article (November 15, 2022).
View the most recent version of this article

Original research

Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Vergote I, Van Nieuwenhuysen E, De Waele S, et al

Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group

International Journal of Gynecologic Cancer Published Online First: 21 January 2022. doi: 10.1136/ijgc-2021-003190

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password